Ionis Pharmaceuticals, Inc.
1021 articles about Ionis Pharmaceuticals, Inc.
-
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
3/25/2024
Ionis Pharmaceuticals, Inc. announced today that it will present positive Phase 3 Balance results in patients with familial chylomicronemia syndrome (FCS) for the company's lead independent, investigational medicine, olezarsen, at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia.
-
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
-
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
3/13/2024
Ionis Pharmaceuticals, Inc. announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis, previously referred to as nonalcoholic steatohepatitis.
-
The biotech announced Wednesday that patients on ION224 had histologic improvement in the liver disease without worsening of fibrosis. Ionis’ mid-stage win comes as the FDA is set to decide whether to approve rival Madrigal’s resmetirom by Thursday.
-
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
2/29/2024
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Kyle Jenne has rejoined Ionis as executive vice president, chief global product strategy officer, to lead all aspects of commercialization at the Company.
-
Ionis to present at upcoming investor conferences - February 28, 2024
2/28/2024
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences.
-
Ionis reports fourth quarter and full year 2023 financial results
2/21/2024
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
2/15/2024
Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to the investigational medicine olezarsen for the treatment of familial chylomicronemia syndrome, a rare, genetic disease characterized by extremely elevated triglyceride levels and recurrent acute pancreatitis.
-
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
2/8/2024
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults.
-
Ionis to hold fourth quarter and full year 2023 financial results webcast
2/7/2024
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results.
-
Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
1/30/2024
Vect-Horus today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).
-
The company said it’s preparing to file a New Drug Application with the FDA on the strength of late-stage study data for its investigational RNA-targeted donidalorsen in patients with hereditary angioedema.
-
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
1/22/2024
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema (HAE).
-
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
1/8/2024
Ionis Pharmaceuticals, Inc. announced highlights from the Company's 2023 achievements and previewed a number of important milestones expected in 2024.
-
Wainua, which is jointly developed and commercialized by AstraZeneca and Ionis Pharmaceuticals, was given the FDA’s green light on Thursday and will now compete with Alnylam’s two approved hATTR-PN therapies.
-
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
12/21/2023
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.
-
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
12/20/2023
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia , Ph.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Wednesday, January 10, 2024.
-
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
12/18/2023
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).
-
The year may be coming to a close, but there's no holiday break for the FDA, which will release five regulatory verdicts over the next two weeks.
-
Ionis announces the appointment of Michael Yang to Board of Directors
12/14/2023
Ionis Pharmaceuticals, Inc. announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors.